Bymetric
UK company intelligence
Spinout Active LTD

Company profile

Bloomsbury Genetic Therapies Limited

UK company 13593877, incorporated on 31 August 2021.

Bloomsbury Genetic Therapies Dedicated to delivering the promise of gene therapy

Bloomsbury Genetic Therapies Limited is a UK company with status Active founded in 2021 based in East of England.

Company number
13593877
Incorporated
31 Aug 2021
Companies House status
Active

Company identity

Browse spinouts
Founded / incorporated
31 August 2021

Company number 13593877

Verify at Companies House
Legal name
BLOOMSBURY GENETIC THERAPIES LIMITED
Company type
Private Limited Company
Region
East of England
Registered address
BUILDING 1000 CAMBRIDGE RESEARCH PARK
BEACH DRIVE
WATERBEACH
CAMBRIDGESHIRE
ENGLAND
CB25 9PD
Insolvency history
No

Corporate ownership

Updated 07 Jul 2026 09:49

3 levels 2 ultimate controllers
1
Company Active LTD
Bloomsbury Genetic Therapies Limited
CRN 13593877
2
Direct and ultimate controller Active LTD
Ucl Ventures Limited
CRN 02776963
3
Direct controller Active LLP
Utf General Partner 2 LLP
CRN OC425247
4
Intermediate controller Active LTD
Utf Albion Member Limited
CRN 09894947
5
Intermediate controller Active LTD
Utf Albion Member 2 Limited
CRN 09894949
6
Ultimate controller Active LLP
Albionvc LLP
CRN OC341254

Company events

Reference milestones and recent Companies House filing stream events.

5 events
30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

13 Sep
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Aug
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

31 Aug
2021

Incorporated

Inception

Company registered at Companies House

Spinout profile

7 entries

Company description

Bloomsbury Genetic Therapies utilises gene therapies to develop treatments for rare neurological and metabolic diseases.

The company aims to translate AAV gene therapy programmes in to paediatric patients affected by rare genetic diseases.

Project impact

The company was created end of 2021 and will take over some academic projects, including the HORACE trial for paediatric ornithine transcarbamylase deficient patients.

The company has just formed but the first clinical trial will start imminently for one of the programmes and another of the programmes has just been granted orphan drug designation.

Not yet

Bloomsbury Genetic Therapies
2021
http://bloomsburygtx.com
Bloomsbury Genetic Therapies
2021
https://bloomsburygtx.com/
Bloomsbury Genetic Therapies
2021
http://bloomsburygtx.com
Bloomsbury Genetic Therapies
2021
http://bloomsburygtx.com
Bloomsbury Genetic Therapies
2021
http://bloomsburygtx.com
Bloomsbury Genetic Therapies
2021
http://bloomsburygtx.com
BLOOMSBURY GENETIC THERAPIES LIMITED
2021